HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.

AuthorsPeter Jenner
JournalNeurology (Neurology) Vol. 63 Issue 7 Suppl 2 Pg. S13-22 (Oct 12 2004) ISSN: 1526-632X [Electronic] United States
PMID15477581 (Publication Type: Journal Article, Review)
Chemical References
  • Amphetamines
  • Antiparkinson Agents
  • Indans
  • Monoamine Oxidase Inhibitors
  • Neuroprotective Agents
  • Oxepins
  • Propylamines
  • dibenzo(b,f)oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine
  • rasagiline
  • propargylamine
  • Selegiline
  • Pargyline
Topics
  • Amphetamines (metabolism)
  • Animals
  • Antiparkinson Agents (pharmacology, therapeutic use)
  • Apoptosis (drug effects)
  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Haplorhini
  • Humans
  • Inactivation, Metabolic
  • Indans (pharmacology, therapeutic use)
  • Mice
  • Mice, Transgenic
  • Models, Neurological
  • Monoamine Oxidase Inhibitors (pharmacology, therapeutic use)
  • Neurons (drug effects, pathology)
  • Neuroprotective Agents (pharmacology, therapeutic use)
  • Oxepins (pharmacology, therapeutic use)
  • Oxidative Stress
  • Pargyline (analogs & derivatives, chemistry, pharmacology)
  • Parkinson Disease (drug therapy, enzymology, pathology)
  • Propylamines (chemistry, pharmacology)
  • Selegiline (pharmacokinetics, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: